Carmustine ( DrugBank: Carmustine )


5 diseases
IDDisease name (Link within this page)Number of trials
11Myasthenia gravis1
13Multiple sclerosis/Neuromyelitis optica2
14Chronic inflammatory demyelinating polyneuropathy1
28Systemic amyloidosis1
60Aplastic anemia1

11. Myasthenia gravis


Clinical trials : 332Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

14. Chronic inflammatory demyelinating polyneuropathy


Clinical trials : 175Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

28. Systemic amyloidosis


Clinical trials : 267Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

60. Aplastic anemia


Clinical trials : 245Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries